-
公开(公告)号：KR1020120139313A
公开(公告)日：2012-12-27
申请号：KR1020110059048
申请日：2011-06-17
Applicant: 전북대학교산학협력단
CPC classification number: A61K38/465 , C12Y301/01004 , A61K35/63
Abstract: PURPOSE: A composition containing phospholipase A2(group III sPLA2) isolated from bee venom is provided to control neurodegenerative factor activation and to prevent and treat neurodegenerative diseases. CONSTITUTION: A composition which regulates AKT or p-38 MAPK expression contains bee venom phospholipase A2(group III sPLA2) as an active ingredient. The composition further contains pharmaceutically acceptable carriers or diluents. A composition for treating neurodegenerative diseases contains the bee venom phospholipase A2(group III sPLA2) as an active ingredient and also contains pharmaceutically acceptable carriers or diluents. The composition is manufactured in the form of a suspension, freeze-dried agent, non-aqueous injection, or aqueous injection.
Abstract translation: 目的：提供从蜂毒中分离的含有磷脂酶A2（组III sPLA2）的组合物，用于控制神经变性因子的活化并预防和治疗神经变性疾病。 构成：调节AKT或p-38 MAPK表达的组合物含有蜂毒素磷脂酶A2（组III sPLA2）作为活性成分。 组合物还含有药学上可接受的载体或稀释剂。 用于治疗神经变性疾病的组合物含有蜂毒素磷脂酶A2（组III sPLA2）作为活性成分，并且还含有药学上可接受的载体或稀释剂。 该组合物以悬浮液，冻干剂，非水性注射剂或水性注射剂的形式制备。
-
Patent Agency Ranking
公开(公告)号：KR1020120118784A
公开(公告)日：2012-10-29
申请号：KR1020110036383
申请日：2011-04-19
Applicant: 전북대학교산학협력단
IPC: A61K31/133 , A61P19/02 , A61P29/00
Abstract: PURPOSE: A rheumatic or arthritic disorder treating composition which contains sphingosine 1-phosphate is provided to suppress various inflammatory factors. CONSTITUTION: A rheumatic or arthritic disorder treating composition comprises pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients. An inflammatory inducer is cyclooxygenase-2, inducible nitric oxide synthesis or NFkB(nuclear factor kB). The composition suppressing the chondrocyte inflammation contains pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients. The composition for treating the rheumatic or arthritic disorder contains pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients. The rheumatic or arthritic disorder is rheumatoid arthritis, degenerative arthritis, ankylosing spondylitis or osteoporosis. The composition which obstructs the inflammatory inducer contains pharmaceutically acceptable carrier or diluent and sphingosine 1-phosphate as active ingredients.
Abstract translation: 目的：提供含有鞘氨醇1-磷酸的风湿或关节炎病症治疗组合物，以抑制各种炎症因素。 构成：风湿性关节炎病症治疗组合物包含药学上可接受的载体或稀释剂和1-磷酸鞘氨醇作为活性成分。 炎症诱导剂是环氧合酶-2，诱导型一氧化氮合成或NFkB（核因子kB）。 抑制软骨细胞炎症的组合物含有药学上可接受的载体或稀释剂和1-磷酸鞘氨醇作为活性成分。 用于治疗风湿性关节炎病症的组合物含有药学上可接受的载体或稀释剂和1-磷酸鞘氨醇作为活性成分。 风湿性关节炎疾病是类风湿性关节炎，退行性关节炎，强直性脊柱炎或骨质疏松症。 阻碍炎症诱导剂的组合物含有药学上可接受的载体或稀释剂和1-磷酸鞘氨醇作为活性成分。
-
公开(公告)号：KR101351597B1
公开(公告)日：2014-01-16
申请号：KR1020120053201
申请日：2012-05-18
Applicant: 전북대학교산학협력단
Abstract: 본 발명은 초유 유래 락토페린을 이용한 변형 프리온 단백질에 의해 유도되는 세포자멸사의 억제방법에 관한 것이다. 본 발명에 의하면, 락토페린을 처리함으로써 변형 프리온 단백질에 의해 유발되는 활성 산소종의 생성을 감소시켜 세포자멸사를 효과적으로 억제할 수 있다.
-
公开(公告)号：KR1020130142227A
公开(公告)日：2013-12-30
申请号：KR1020120064387
申请日：2012-06-15
Applicant: 전북대학교산학협력단
IPC: A61K31/137 , C07C215/36 , C07C215/10 , A61P25/28
Abstract: The present invention relates to a composition for preventing and treating neurodegenerative brain diseases derived from transformed prion protein which contains one compound selected from the group consisting of fingolimod (2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol), phosphate thereof, and pharmaceutically acceptable salt thereof. By producing medicines and health functional foods using the composition, bovine spongiform encephalopathy, variant Creutzfeldt-Jakob disease, scrappy disease, chronic wasting disease, and contagious spongiform encephalopathy, and other diseases are capable of being prevented and treated. [Reference numerals] (AA,EE) Comparative example 1;(BB,FF) Example 1;(CC) Annexin V-FITC;(DD) Annexin V (%)
Abstract translation: 本发明涉及用于预防和治疗由转化朊蛋白衍生的神经变性脑疾病的组合物，其含有选自芬戈莫德（2-氨基-2- [2-（4-辛基苯基）乙基]丙烷-1 ，3-二醇），其磷酸盐及其药学上可接受的盐。 通过使用该组合物生产药物和保健功能性食品，能够预防和治疗牛海绵状脑病，变异型克雅氏病，刮伤疾病，慢性消耗性疾病和传染性海绵状脑病等疾病。 （AA，EE）比较例1（BB，FF）实施例1（CC）膜联蛋白V-FITC;（DD）膜联蛋白V（％）
-
公开(公告)号：KR1020130128961A
公开(公告)日：2013-11-27
申请号：KR1020120053201
申请日：2012-05-18
Applicant: 전북대학교산학협력단
CPC classification number: A61K38/40 , A61K38/1761 , C07K14/4747 , C07K14/79
Abstract: The present invention relates to an inhibiting method of apoptosis caused by modified prion protein using lactoferrin derived from colostrum. The apoptosis is capable of being effectively controlled by reducing the generation of active oxygen species which is caused by the modified prion protein by processing the lactoferrin.
Abstract translation: 本发明涉及使用来自初乳的乳铁蛋白，由修饰的朊病毒蛋白引起的细胞凋亡的抑制方法。 通过加工乳铁蛋白减少由修饰的朊病毒蛋白引起的活性氧的产生，能够有效地控制细胞凋亡。
-
公开(公告)号：KR101299512B1
公开(公告)日：2013-08-22
申请号：KR1020110036383
申请日：2011-04-19
Applicant: 전북대학교산학협력단
IPC: A61K31/133 , A61P19/02 , A61P29/00
Abstract: 본 발명은 본 스핑고신-1-포스페이트 (sphingosine-1-phosphate)를 유효성분으로 함유하는 관절염 치료용 조성물에 관한 것으로서, 약학적으로 수용 가능한 담체 또는 희석제와 함께 유효성분으로서 스핑고신 1-포스페이트를 함유하는 조성물은 관절염과 관련된 염증유발 인자를 저해하는 것을 특징으로 하며, 본 발명에 따른 조성물은 연골에서 여러 염증인자를 억제하는 효과를 나타내기 때문에 새로운 관절염 치료제의 표적이 될 수 있고, 다양한 관절염 치료제의 개발로 이어질 수 있다.
-
-
-
-
-
Search Results
16
records
(took 0.021 seconds)
